Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 27 Sep 2018
Price : $35 *
At a glance
- Drugs Ulixertinib (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors BioMed Valley Discoveries
- 19 Sep 2018 Status changed from active, no longer recruiting to completed.
- 17 Jan 2018 Planned End Date changed from 1 Jul 2017 to 1 Feb 2019.
- 17 Jan 2018 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History